Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechNSE:CONCORDBIO -0.34%89 Net Margin % is 22.41% as of Jun. 2026, which is 27% below its 10-year median of 30.87. GuruFocus rates NSE:CONCORDBIO with a GF Score™ of 89/100 and a GF Value™ of ₹1,681.38 (Fairly Valued). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, Concord Biotech ranks better than 88.24% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Concord Biotech's Net Income for the
three
months ended in Jun. 2026 was ₹577 Mil. Concord Biotech's Revenue for the
three
months ended in Jun. 2026 was ₹2,575 Mil. Therefore, Concord Biotech's net margin for the quarter that ended in Jun. 2026 was 22.41%.
The historical rank and industry rank for Concord Biotech's Net Margin % or its related term are showing as below:
NSE:CONCORDBIO'
s Net Margin % Range Over the Past 10 Years
Min: 24.65 Med: 30.87 Max: 38.89
Current: 24.65
NSE:CONCORDBIO's Net Margin % is ranked better than 88.24% of 944
companies
in the Biotechnology industry
Industry Median: -76.745
vs NSE:CONCORDBIO: 24.65
Concord Biotech (NSE:CONCORDBIO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Concord Biotech Net Margin % Related Terms
Concord Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CONCORDBIO vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Concord Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (NSE:CONCORDBIO) has a Net Margin % of 22.41% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Concord Biotech and its competitors. This is 27% below median its historical median of 30.87. Over the past decade, Concord Biotech's Net Margin % has ranged from 24.65 to 38.89. According to the industry distribution chart, Concord Biotech ranks #111 out of 944 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Concord Biotech's Net Margin % too high?
Concord Biotech's current Net Margin % of 22.41% is 27% below median its 10-year median of 30.87. Over the past 10 years, this metric has ranged from a low of 24.65 to a high of 38.89. Based on the distribution chart, Concord Biotech ranks #111 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #111 out of 944 companies for Net Margin %. This places Concord Biotech in the top 12% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own Net Margin % has ranged from 24.65 to 38.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Concord Biotech and its competitors. Concord Biotech's current Net Margin % is 22.41%, which is 27% below median its own 10-year median of 30.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (NSE:CONCORDBIO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,681.38, compared to a current price of ₹1,571.30 — trading 6.5% below its estimated fair value. The current Net Margin % is 22.41%, which is 27% below median its 10-year median of 30.87. Concord Biotech's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Concord Biotech (NSE:CONCORDBIO), the current Net Margin % is 22.41% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (NSE:CONCORDBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,571.30 is trading 6.5% below its estimated GF Value™ of ₹1,681.38.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for NSE:CONCORDBIO:
Net Margin %: 22.41% (27% below median its 10-year median of 30.87)
GF Value™: ₹1,681.38 vs. price of ₹1,571.30 (6.5% below fair value)
No single metric tells the full story. See the NSE:CONCORDBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for NSE:CONCORDBIO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CONCORDBIO has been successfully added to your 
